Healthcare performance marketing
Healthcare acquisition,bought on downstream economics.
A performance marketing partner for healthcare and patient acquisition. We connect paid media to qualified patient outcomes — not lead volume.
Focus areas include clinical-trial recruitment, virtual care, and condition-specific patient acquisition.
Our operating principle
Most healthcare acquisition is optimized to the earliest conversion event the platform can reliably observe. We connect media decisions to the downstream patient outcomes that actually determine economics.
Impressions, clicks, and form-fills are all measurable in the ad account. Downstream qualification, screening, consultation, and enrollment are not always visible there — so that is where many acquisition programs stop looking, and where the economics quietly break.
The problem
Cheap leads are the most expensive thing you can buy.
Every metric an ad platform optimizes toward sits upstream of the number that actually funds the trial.
Lead volume is a vanity metric
Ten thousand cheap form-fills mean nothing if none of them screen in. Cost-per-lead hides the number that funds the trial: cost per enrollment.
Unqualified leads burn site capacity
Every ineligible referral your coordinators chase is time stolen from patients who could actually randomize. Bad leads have a real, compounding cost.
Screen-fail waste eats the budget
When targeting ignores inclusion and exclusion criteria, you pay full CPA for traffic that was never eligible in the first place.
Most vendors are blind past the click
Without downstream data, agencies optimize to whatever the ad platform rewards. We wire spend to screening and enrollment outcomes instead.
What we do
Channel work and funnel work, held to the same number.
Three disciplines that only work together: buying the media, qualifying what it produces, and measuring far enough down the funnel to know which is which.
Our approach
Performance-media discipline, applied to a regulated funnel.
We come from performance marketing, where nobody gets paid for traffic that doesn't convert. That discipline is the whole product.
Unit-economics-first testing
Every campaign is a controlled test with a payback threshold. We scale what clears the math on cost per enrollment and kill what doesn't — fast.
Quality over volume, by design
Pre-qualification and exclusion criteria are built in from day one, so the leads we deliver are the ones your sites can actually enroll.
Optimized to downstream conversion
We reconcile downstream outcomes back to source and use them to guide targeting, bidding strategy, creative, funnel work, and budget allocation.
P&L discipline, applied to acquisition
We set economic thresholds before launch and treat media as an investment against downstream outcomes — not a volume target.
Process
Four steps, one number.
Model the economics before spending, test in structured form, screen hard, then optimize against whatever downstream signal exists.
Audit & model the economics
Before any spend, we work out what an enrolled patient can cost and still make the trial's recruitment budget work.
Launch & test in market
Structured tests across channels, sized to reach a readable signal rather than simply spend the budget.
Qualify & route
Qualification and routing logic filter or redirect mismatched demand before it consumes avoidable operating capacity.
Optimize & report
Downstream outcomes are reconciled to source and used to guide media and funnel decisions.
FAQ
The questions healthcare teams actually ask.
We typically start with a one-to-two month test window and a media budget large enough to produce a useful read on qualification and downstream economics. The right threshold depends on the patient journey, geography, conversion rate, and value of the downstream outcome. We'll tell you honestly on the first call if the available volume or budget is too small to learn anything.
Yes. Clinical-trial recruitment is one of our specialties, so we can work with sponsors, CROs, site networks, or sites where the operating model makes sense. Across healthcare more broadly, the important question is the same: can the engagement give us enough downstream outcome data to judge acquisition on more than lead volume?
Enrollment economics. Cost per lead is a checkpoint, not the goal. In clinical-trial recruitment we reconcile screening and enrollment outcomes back to source; in other healthcare models the equivalent may be a qualified patient, booked visit, completed consultation, treatment start, or another downstream outcome that actually determines the economics.
We design measurement so patient-level health information stays in the approved intake, EHR, CRM, CTMS, or clinical system rather than being disclosed to an ad platform. Downstream outcomes can still be reconciled to source for reporting and media decisions using the minimum data necessary and an agreed workflow. Any platform-side conversion signal is limited to data permitted by that platform's terms and the applicable privacy framework. Where we handle PHI on behalf of a HIPAA-regulated client, the required BAA and data-handling controls are agreed before launch.
Next step
Tell us what you're trying to acquire.
Share the patient journey, geography, economics, and acquisition goal. We'll tell you honestly whether we're the right partner.